Evaluating the Automated Accellix® Platform Against Conventional Flow Cytometry for Cell Therapy Samples

DOWNLOAD POSTER

Evaluating the Automated Accellix^® Platform Against Conventional Flow Cytometry for Cell Therapy Samples

Sanika Gad¹, Harish Adoni¹, Mike Giffin¹, Adriana Geldart¹, Mike Paglia¹, Josh Pirkle¹, Alianna Provenca¹, Farah Shahjin¹, Arianna Spooner¹, Tam Nguyen¹, Miranda Williams¹, Aaron Hoover¹, Sharlene Amador¹, Chesney Michels¹, Jacob van Vloten², Elaine Than², Félix A. Montero Julian²
¹ElevateBio Basecamp, Waltham, MA, USA; ²Accellix, Inc., San Jose, CA

ATW 2026 | February 9 – 12 | San Diego, USA

Description: Cell therapy manufacturing requires rapid, reliable cell phenotyping to guide critical process decisions. However, conventional flow cytometry often presents challenges including lengthy turnaround times, complex workflows and the need for specialized expertise in Flow cytometry. This poster presents a comparison between the Accellix Platform using off-the-shelf assays and conventional flow cytometry across representative cell therapy samples. We evaluated:

3 lots of cryopreserved PBMCs (representing incoming starting material)
3 lots of PBMCs treated with T-cell activation reagents (representing in-process samples)
3 lots of cryopreserved CD19 CAR-T drug product (representing pooled/final drug product)
Streck CD-Chex Plus® control material to verify assay performance and allow for standardization and validation

Our results demonstrate that the Accellix platform achieves data quality comparable to conventional methods while substantially reducing turnaround time and operational complexity.

Provide the following information and we’ll email you a copy of the poster:

*Required field

First Name*

Last Name*

Job Title*

Name of Institution*

Telephone

Email*

City*

State*

Country/Region*

Interest*

Cell Therapy Manufacturing QCStem Cell Transplant Enumeration & PhenotypingBlood Donor Phenotyping

I consent to receive occasional email communications from Accellix (e.g., product updates, technical resources, event announcements, promotions). I understand that I can unsubscribe at any time. View our Privacy Policy.

Please leave this field empty.

Since January 22nd, 2026, Accellix is part of bioMérieux, a world leader in the field of in vitro diagnostics.

Evaluating the Automated Accellix^® Platform Against Conventional Flow Cytometry for Cell Therapy Samples

Provide the following information and we’ll email you a copy of the poster:

U.S. Office

Israel Office